does glp 1 reduce alcohol consumption A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during in people with obesity GLP-1 & Alcohol 2026: Can

There's no single way to think about GLP-1 medications

Despite these findings, this association between HbA1c reduction and stroke risk reduction does not necessarily indicate that glycemic control is the sole actor in GLP-1RA-mediated stroke protection

Depending on the patients condition, doctors may focus on managing vascular risk factors, monitoring the affected and unaffected eye, and evaluating possible interventions on a case-by-case basis such as prescribing medication such as corticosteroids (e.g., prednisone) to reduce inflammation and improve blood flow to the optic nerve, anticoagulants (e.g., aspirin) to help prevent blood clots that could block blood flow to the optic nerve and angiogenesis inhibitors (e.g., bevacizumab) to try to block the growth of abnormal blood vessels that can damage the optic nerve

Work with a functional or integrative provider to optimize your intake while still allowing fat loss

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status